Moderna Shares Fall as Cancer Vaccine Data Leaks Ahead of Full Presentation
Moderna shares dropped as much as 25% after partial phase 3 data on its personalised melanoma vaccine, developed with Merck, leaked before its scheduled presentation, even though the results beat Wall Street expectations.